SHORT REPORT

Generation and immunogenicity analysis of recombinant classical swine fever virus glycoprotein E2 and E\textsuperscript{ns} expressed in baculovirus expression system

Qiang Wei\textsuperscript{1†}, Yilin Bai\textsuperscript{1,2†}, Yapeng Song\textsuperscript{1,3†}, Yunchao Liu\textsuperscript{1}, Wei Yu\textsuperscript{1,2}, Yaning Sun\textsuperscript{1,4}, Li Wang\textsuperscript{1}, Ruiguang Deng\textsuperscript{1}, Guangxu Xing\textsuperscript{1} and Gaiping Zhang\textsuperscript{1,3,5*}

Abstract
Classical swine fever (CSF) caused by the classical swine fever virus (CSFV) is a highly contagious swine disease resulting in large economical losses worldwide. The viral envelope glycoprotein E2 and E\textsuperscript{ns} are major targets for eliciting antibodies against CSFV in infected animals. In this report, the glycoprotein E2 and E\textsuperscript{ns} were expressed using the baculovirus system and their protective immunity in rabbits were tested. Twenty CSFV seronegative rabbits were randomly divided into five groups. Each rabbit was intramuscularly immunized with CSFV-E2, CSFV-E\textsuperscript{ns}, or their combination (CSFV-E2 + E\textsuperscript{ns}). Besides, a commercial CSFV vaccine (C-strain) and PBS were used as positive or negative controls, respectively. Four weeks after the second immunization, all the rabbits were challenged with 100 RID\textsubscript{50} of CSFV C-strain. High levels of CSFV E2-specific antibody, neutralizing antibody and cellular immune responses to CSFV were elicited in the rabbits inoculated with C-strain, CSFV-E2, and CSFV-E2 + E\textsuperscript{ns}. And the rabbits inoculated with the three vaccines received complete protection against CSFV C-strain. However, no neutralizing antibody was detected in the E\textsuperscript{ns} vaccinated rabbits and the rabbits exhibited fever typical of CSFV, suggesting the E\textsuperscript{ns} alone is not able to induce a protective immune response. Taken together, while the E\textsuperscript{ns} could not confer protection against CSFV, E2 and E2 + E\textsuperscript{ns} could not only elicit humoral and cell-mediated immune responses but also confer complete protection against CSFV C-strain in rabbits.

Keywords: Classical swine fever virus, Immunogenicity, E2, E\textsuperscript{ns}

Introduction
Classical swine fever (CSF) is a highly contagious and economically important viral disease of swine, that is notifiable to the World Organization for Animal Health [1]. The causative agent, classical swine fever virus (CSFV) is a member of the genus Pestivirus within the family Flaviviridae. The CSFV positive-stranded RNA genome consists of a single long open reading frame encoding a polyprotein of approximately 3900 amino acids. The polyprotein is cleavage processed by cellular and viral proteases to the mature forms of final viral proteins. The viral proteins include four structural proteins (the nucleocapsid protein C, E1, E2, and E\textsuperscript{ns}) and eight nonstructural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B, and N\textsuperscript{pro}) [2].

There are three envelope glycoproteins in the CSFV virion, E\textsuperscript{ns}, E1, and E2. E\textsuperscript{ns} is loosely associated with mature virions [3] and possesses ribonuclease activity.
[4]. It is heavily glycosylated with carbohydrate moieties at seven N-linked glycosylation sites and glycosylation contributes to nearly half of the molecular mass of the protein [5–7]. E2 is a major determinant of CSFV virulence and is involved in virus attachment and entry into target cells [8, 9]. It is shown that glycosylation plays a major role in the immunogenicity of CSFV envelope proteins [7]. In addition, previous studies demonstrate that both E2 and Erns are capable of inducing the production of neutralizing antibodies in the host [10–12].

The modified live virus (MLV) vaccines based on C-strain are effective and provide complete protection against the CSFV. However, the conventional vaccines could not offer differentiability of infected from vaccinated animals. Thus, subunit vaccines are designed to meet the DIVA (differentiation of infected from vaccinated animals) requirement for vaccination. The two CSFV envelope glycoproteins Erns and E2 have been targeted for subunit vaccine development. Most of the studies have been focused on the E2 and the protein is well recognized as the protective antigen [13–17]. In contrast, the effectiveness of Erns as a vaccine target has been controversial in different studies. It is shown that single administration of purified Erns glycoprotein could induce an effective protection against CSFV infection in a previous study [7]. However, another study showed that recombinant Erns expressed in yeast P. pastoris could not induce neutralizing antibody and protection against CSFV infection [18]. Thus, further investigation is needed to evaluate the immunogenicity of the protein and its ability to induce protection against CSFV.

In the present study, two recombinant baculoviruses were constructed to separately express E2 and Erns. The glycosylation of the two protein was analyzed and the protective immune responses of the recombinant protein E2, Erns or E2 + Erns to CSFV were investigated in a rabbit model.

Materials and methods
Cell line and virus strain
Porcine kidney cells (PK-15) were grown and maintained in DMEM (Gibco) supplemented with 10% fetal bovine serum (Hyclone) and 1% Penicillin–streptomycin solution (Gibco). Spodoptera frugiperda 21 insect cells (Sf21) were grown in SF-900II medium at 27 °C. The commercial vaccine (C-strain) was purchased from GuangDong YongShun Biological Co., Ltd (China) for immunization and challenge in the animal experiments. CSFV Shimen strain was passaged four times in PK-15 cells cultured in DMEM supplemented with 10% FBS in order to be used for the serum neutralization test and the lymphocyte proliferation assay.

Plasmid construction
For secretory expression of the protein, the gp67 signal peptide was inserted into the vector pFastBac1 with homologous recombination method using the following primers: F: 5′-CCACCATCGGGCGGGATCTGAC TACTAGTAAATCAGTCACCAAAGGCTTCAATAAGGAACACAAGCAAGATG GTAAGGGC-3′ and R: 5′-GCAAAGATGTGTAAGGAACACAAGCAAGATG GTAAGGGC-3′. The resulting plasmid was designated as pFastBac1-gp67. For secretory expression of E2, the C-terminal transmembrane region was deleted [19–21]. Consequently, the coding sequence for the amino acid residues 1–331 of E2 was cloned into the pFastBac1-gp67, with a C-terminal 6×His tag fused to the fragment. The Erns gene (the amino acid residues 1–190) containing the mainly antigenic region [22–24] was also cloned into the pFastBac1-gp67, with a C-terminal 6×His tag fused to the fragment. This truncation was meant to avoid aggregation during secretion and purification due to the amphipathic helix at the C terminus that is inserted slightly tilted into the membrane [25–27].

Protein expression and purification
The recombinant plasmids were transformed into Escherichia coli DH10Bac. Upon screening of colonies, positive colonies were subcultured in LB broth. And the recombinant bacmid of E2 or Erns was isolated using Qiagen plasmid mini kit. Then the recombinant baculovirus was generated using the Bac-to-Bac system (Invitrogen). Sf21 cells were infected for large-scale protein production. The cell cultures were collected and clarified by centrifugation at 9000 × g for 20 min. E2 and Erns protein were purified using the nickel-affinity chromatography followed by size-exclusion chromatography (HiLoad 16/60, Superdex 200; GE Healthcare). The proteins were verified by SDS-PAGE and subsequently by western blot using anti-His antibody. The protein concentration was quantified with a Micro BCA™ protein assay kit 120 (Pierce Biotechnology, USA).

Preparation of vaccines
The CSFV subunit vaccines, CSFV-E2 and CSFV-Erns were produced by mixing the antigen with ISA 201 adjuvant (Seppic, France) at a ratio of 50:50 (w/w) according to the manufacturer’s instructions (100 μg of the E2 or Erns protein per 2 mL). The subunit vaccine CSFV-E2 + Erns containing 100 μg of E2 protein and 100 μg of Erns protein per 2 mL was manufactured with the same method.
Vaccination and challenge in rabbits
Twenty 14-week-old female New Zealand white rabbits (Hualan Biological Engineering INC, Xinxiang, China) were randomly divided into 5 groups (n = 4). Groups A–C were immunized with 2 mL of CSFV-E2, CSFV-E11, and CSFV-E2 + E11, respectively. Group D was inoculated with 100 RID50 (50% rabbit infectious dose) of the commercial C-strain vaccine as positive control. Group E was inoculated with 2 mL of PBS as negative control. Booster immunization was given at the same dose at 4 weeks post primary immunization. All the rabbits were intravenously challenged with 100 RID50 of CSFV (C-strain) at 4 weeks after booster immunization. After challenge, rectal temperatures were recorded every 12 h to detect the typical fever of rabbits. A typical fever is characterized by a ≥ 1 °C increase in rectal temperature for a minimum of 18 h.

Measurement of anti-E2 and anti-E11 antibodies using ELISA assays
The presence of E2-specific antibody was determined by blocking ELISA with IDEXX CSF antibody test kit (IDEXX GmbH, Switzerland) according to the manufacturer’s instructions. All samples were tested in triplicate and the optical density was measured at 450 nm (OD450) with an ELISA plate reader (POLARstar Omega, Germany). The mean OD450 of the negative controls was more than 0.5 and the mean blocking rate of the positive controls (NCx) was greater than 50%, thus the assay was considered valid. The results were reported as the antibody blocking rate. The blocking rate was calculated with the equation, blocking rate = 100 × NCx – SampleOD450 / NCx. A blocking rate ≤ 30% was interpreted as negative, a blocking rate between 30% and 40% was interpreted as suspected, and a rate ≥ 40% was interpreted as positive.

Anti-E11 antibodies were determined by ELISA. Briefly, the 96-well flat-bottomed microtiter plates were coated overnight at 4 °C with 10 µg/mL of purified E11 protein (100 µL/well) in coating buffer (0.1 M carbonate buffer, pH 9.6). Subsequently, the plates were washed with PBST (PBS containing 0.05% Tween-20) for three times. Next, the serum samples (50 µL /well, in duplicate) were added to the plates and incubated for 1 h at room temperature. Then, horseradish peroxidase (HRP)-conjugated goat anti-swine IgG (Jackson ImmunoResearch, West Grove, PA, USA) was used as secondary antibody. The plates were developed using TMB stabilized chromogen, and the reactions were stopped with 2 N sulfuric acid. Relative antibody concentrations were determined using the ELISA plate reader (POLARstar Omega, Germany) at 450 nm.

Serum neutralization test
The serum neutralization test was performed to detect CSFV antibodies as previously described [16]. Briefly, the serum samples were inactivated for 30 min at 56 °C. They were then serially diluted two-fold with PBS. The diluted serum samples (in duplicate) were incubated with 100 TCID50 of CSFV Shimen strain for 1 h at 37 °C in 5% CO2. Residual virus infectivity was determined by adding 1.0 × 104 PK-15 cells to each well and incubated at 37 °C in 5% CO2 for 3 days. Subsequently, the cells were subjected to immunoperoxidase monolayer assay (IPMA). Firstly, the cells were fixed with methanol containing 3% H2O2 at room temperature for 10 min. After washing three times with PBST, cells were incubated with blocking buffer containing 5% skim milk at 4 °C overnight. Then, cells were incubated with hyperimmune porcine CSFV antiserum (prepared in our lab) and followed by HRP-conjugated goat anti-swine IgG (Jackson ImmunoResearch, West Grove, PA, USA). Finally, cells were stained with AEC solution (ZSGB-BIO, Beijing, China) at room temperature and examined by light microscopy. Samples of CSFV positive reference serum (Institute of Veterinary Drug Supervision of China, Beijing, China) and CSFV-negative serum (prepared in our lab) were used as control samples. The titers of CSFV specific neutralization antibodies were expressed as the reciprocal of the highest dilution that caused 50% neutralization.

Lymphocyte proliferation assay
Peripheral blood mononuclear cells (PBMCs) were isolated from the immunized rabbits at 49 days post immunization using the rabbit lymphocyte isolation kit (Solarbio, China) and resuspended in RPMI 1640 medium containing 10% FBS. The cells (1 × 106 cells/mL) were seeded into 96-well plates with 100 µL per well and then stimulated with CSFV Shimen strain or unstimulated. All treatments were performed in triplicate. After 72 h of incubation, WST-8 (10 µL/well, Beyotime Biotechnology, China) was added and incubated for a further 1 h at 37 °C. The absorbance of each well was measured using the ELISA plate reader (POLARstar Omega, Germany) at 450 nm. The results were expressed as stimulation index (SI) = mean of the OD450 values of the CSFV-stimulated wells/mean of the OD450 values of CSFV-unstimulated wells.

Analysis of IFN-γ and IL-4 mRNA expression
PBMCs were cultured in 12-well plates for 48 h with or without the stimulation of CSFV Shimen strain. Total RNA was extracted and reverse transcribed in a 20 µL reaction mixture. The cDNA product was further amplified using a SYBR Green Master (Roche)
and specific primers (IFN-γ F: CTGGTCCAGCGT AAAGCAGT and R: TCAGTACTTGGATGCTCG CC; IL-4 F: CAGGGGCCACATCATCCTAC and R: CTGGTTGTGGTCTTGGGG; GAPDH F: AGAGCA CCAGAGGAGGACG and R: TGGGATGAAAACGT GAAGAG) as previously described [16]. Real-time RT-PCR amplification was performed using the following cycling parameters: 10 min at 94 °C, and 40 cycles of 15 s at 94 °C and 60 °C for 30 s. Each experiment was performed in triplicate. In summary, gene expression was determined by relative quantity, which compares the threshold cycle (Ct) of the sample of interest (CSFV-stimulated PBMCs) to the Ct generated by a reference sample (non-stimulated PBMCs). Take IFN-γ as an example, the IFN-γ gene expression was normalized to GAPDH expression by subtraction of Ct to obtain ΔCt values. The ΔΔCt was calculated as the difference between ΔCt values for CSFV-stimulated and non-stimulated PBMCs. The relative difference in IFN-γ expression between stimulated and unstimulated cells was determined using the equation $2^{-\Delta\Delta C t}$ according to the User Bulletin number 2, ABI prism 7500 Sequence Detection System (Applied Biosystems) instructions.

### Detection of CSFV RNA through RT-NestPCR assay

The rabbits were euthanized at 4 days after challenge and the spleens were collected under sterile conditions. The total RNA was extracted and reverse transcribed. For RT-NestPCR [28], cDNAs were prepared for first round PCR with outer primer pairs (Outer-F: 5′-CAA CTGGCTAGTTAATGCA-3′ and Outer-R: 5′-AAT GAGTGTAGTG- TGGTAC-3′) in a 25 μL cocktail containing 2 × rTaq mix (Takara) 12.5 μL, 10 μM Outer-F or Outer-R primer 1 μL, double distilled water 8 μL and cDNA 2.5 μL. The first round PCR steps are as following: initial denaturation at 95 °C for 1 min, 25 cycles at 94 °C for 30 s, 54 °C for 30 s and 72 °C for 30 s, followed by a final extension at 72 °C for 10 min. The first round PCR products were then used as templates for second round PCR with inner primer pairs (Inner-F: 5′-ATGATGATG ACCCTGATA-3′ and Inner-R 5′-GTGTGTAACCTT GAGGTAG -3′) in a 25 μL cocktail containing 2 × rTaq mix 12.5 μL, 10 mM Inner-F or Inner-R primer 1.5 μL, double distilled water 9 μL and first round PCR product 0.5 μL. The second round PCR steps are as following: initial denaturation at 95 °C for 3 min, 35 cycles at 94 °C for 30 s, 56 °C for 30 s and 72 °C for 20 s, followed by a final extension at 72 °C for 10 min. Finally, the amplified products were analyzed by electrophoresis.

### Statistical analysis

Comparisons and graphs were analyzed using GraphPad Prism version 7.0. Differences were considered statistically significant at $p < 0.05$.

### Results

#### Expression and purification of recombinant proteins E2 and E<sup>ms</sup>

CSFV E2 or E<sup>ms</sup> gene from the CSFV shimen strain was cloned into the recombinant baculovirus and the recombinant proteins were expressed using sf21 insect cells. The culture medium was then collected by centrifugation. And the supernatant was subjected to protein purification with Ni-NTA agarose beads. As shown in Fig. 1, recombinant E2 and E<sup>ms</sup> protein were purified from the culture medium. The recombinant E2 protein appeared to be 45 kDa, and the recombinant E<sup>ms</sup> was about 25 kDa. The bands were diffuse and even multiple bands were observed in the analysis of E<sup>ms</sup> protein. Moreover, the proteins ran at higher molecular weight than predicted mass calculated from the amino acid composition, indicating that the two proteins were glycosylated. Accordingly, deglycosylation with PNGase F resulted in a single sharper band and the molecular weights of E2 and E<sup>ms</sup> were approximately 40 kDa and 20 kDa, respectively. Thus, the diffuse or multiple bands may represent different glycosylation levels of the proteins. Taken together, these results suggest the two proteins are glycosylated properly.

#### Humoral immune responses in rabbits

To determine the antibodies elicited against CSFV, we analyzed the serum samples for CSFV E2-specific antibodies (Fig. 2a), E<sup>ms</sup>-specific antibodies (Fig. 2b) and anti-CSFV neutralizing antibodies (Fig. 2c). The results of blocking ELISA were reported as the antibody blocking rate and a rate ≥ 40% was interpreted as positive. As shown in Fig. 2a, the rabbits vaccinated with the commercial CSFV vaccine (C strain), CSFV-E2 and CSFV-E<sup>ms</sup> developed specific E2 antibody responses as early as 7 d post-immunization (dpi), with mean antibody blocking rates of 59.68%, 56.52% and 62.75%, respectively (cut-off value of 40%). The antibody titers induced by CSFV-E<sup>ms</sup> were not detected with blocking ELISA. The antibody levels of all vaccinated rabbits peaked at 56 d, with mean antibody blocking rates of 93.40%, 95.47%, and 95.67%, respectively (Fig. 2a). Moreover, it is shown that the rabbits vaccinated with C strain, CSFV-E<sup>ms</sup> and CSFV-E<sup>2 + E<sup>ms</sup></sup> developed specific E<sup>ms</sup> antibody responses as early as 7 dpi (Fig. 2b).
However, E<sup>Erns</sup>-specific antibody was not detected in the CSFV-E2 and PBS groups.

As shown in Fig. 2c, no neutralization activity against CSFV was detected in the PBS group throughout the experiment. All the rabbits vaccinated with the C strain, CSFV-E2 and CSFV-E2 + E<sup>Erns</sup> developed anti-CSFV neutralizing antibody at 14 dpi and peaked at 56 dpi. Besides, the virus neutralization assay (VNA) titers in the three groups are comparable. In contrast, neutralization antibody was not detected in the CSFV-E<sup>Erns</sup> vaccinated rabbits, showing no significant differences with that of the PBS group. Thus, there seems to be close correlation between VNA titers and levels of E2-specific antibodies.

### Cellular immune responses in rabbits

To evaluate the impact of the recombinant protein on cellular immune response, the CSFV-specific lymphocyte proliferative responses were measured at 49 dpi. As shown in Fig. 3a, the stimulation index (SI) of PBMCs from vaccination groups was significantly greater than the PBS group, although the difference is marginal.

To assess the cellular immune responses further, the mRNA expression levels of IFN-γ and IL-4 were evaluated at 49 dpi through real-time RT-PCR. Cytokine IFN-γ is associated with T helper cell type 1 (Th1) responses and cell-mediated immunity. The amount of IL-4 released by the stimulated PBMCs reflected T helper cell type 2 (Th2) responses of the vaccinated groups. All vaccinated groups, except for the PBS group, elicited higher IFN-γ mRNA expression than IL-4 mRNA expression (Fig. 3b, c). These results indicated that the C strain, CSFV-E2, CSFV-E<sup>Erns</sup>, and CSFV-E2 + E<sup>Erns</sup> vaccines induced Th1-dominant cellular immune responses in vivo.

### Protection of rabbits against CSFV challenge

All rabbits were intravenously challenged with 100 RID<sub>50</sub> of CSFV at 4 weeks after booster immunization. The body temperature responses of individual rabbits were measured (Fig. 4). All rabbits in the PBS group displayed typical fever at 24–72 h post-challenge (Fig. 4a). Besides, all rabbits immunized with CSFV-E<sup>Erns</sup> also exhibited typical fever (Fig. 4d). In contrast, the rabbits immunized with C-strain, CSFV-E2, and CSFV-E2 + E<sup>Erns</sup> were completely
protected and demonstrated normal body temperature at post-challenge (Fig. 4b, c, e).

As shown in Fig. 5, no viral RNA was detected in the rabbits immunized with C-strain, CSFV-E2, and CSFV-E2+E\textsuperscript{Ems}. However, viral RNA was detected both in CSFV-E\textsuperscript{Ems} and PBS groups. The results are consistent with the observed typical fever in different groups.

Discussion

In the present study we successfully constructed recombinant baculoviruses expressing E2 and E\textsuperscript{Ems}. The glycosylation of the two protein is confirmed by PNGase F treatment. We investigated the efficacy of the recombinant E2 and E\textsuperscript{Ems} protein as subunit vaccines against CSFV. The results showed that immunization with CSFV-E2 and CSFV-E2+E\textsuperscript{Ems} induced robust humoral immune responses, which conferred complete protection against the 100RID\textsubscript{50} CSFV C-strain challenge in the rabbit model. In contrast, immunization with CSFV-E\textsuperscript{Ems} could not induce a protective immune response.

In protein engineering, secretory expression is preferred because of cytoxicity of the target proteins or for easier purification of the expression products with less interference from cellular proteins. Here, high yield of E2 and E\textsuperscript{Ems} were obtained from the recombinant baculovirus using the modified pFastBac1 vector containing the gp67 signal peptide. The recombinant protein was secreted into the culture supernatants and could be easily purified using Ni affinity column.

For secretory expression of E2, the transmembrane region was deleted. It was shown that such deletion would not influence the immunogenicity of E2 [19–21]. Although different expression systems have been approached for expression of E2, insect cells maintain many advantages. For instance, insect cells do not produce lipopolysaccharides, which is a concomitant contaminant in proteins expressed in E. coli. In addition, insect cells could provide correct protein folding [29] and
Fig. 3 Cellular immune responses in immunized rabbits. PBMCs isolated from the immunized rabbits at 49 days after the primary vaccination were stimulated with or without CSFV Shimen strain in triplicate. The T-lymphocyte proliferation was performed as described in Materials and Methods. The stimulation index was obtained from dividing mean of the OD450 values of the CSFV-stimulated wells by mean of the OD450 values of CSFV-unstimulated wells. RNA of PBMCs was extracted and subjected to real-time RT-PCR after 72 h of incubation at 37 °C. Relative quantity of IL-4 mRNA expression (b) and IFN-γ mRNA expression (c) were determined using the expression of the GAPDH gene as the housekeeping gene. Data are shown as mean ± SEM, statistical differences between vaccination groups and PBS groups were measured by one-way ANOVA, indicated by asterisk. *p < 0.05; **p < 0.01; ***p < 0.001

Fig. 4 Rectal temperatures of the rabbits after challenge with CSFV C-strain. Rectal temperature was recorded each 12 h-interval throughout the experiment. Fever was considered as rectal temperature ≥ 40 °C and lasting for at least 18 h.
post-translational modifications, which is particularly important for proteins that are to be used as subunit vaccine candidates. Indeed, it has been confirmed that glycosylation of CSFV envelope proteins is crucial for the immunogenicity [7]. As revealed in the SDS-PAGE and western blot analysis, the E2 protein obtained here is glycosylated efficiently, which would facilitate its immunogenic efficacy. To avoid aggregation of E\textsuperscript{rns} during secretion and purification, the amphipathic helix at the C terminus that is inserted slightly tilted into the membrane was truncated [25–27]. Moreover, the antigenic structure and organization of E\textsuperscript{rns} protein was analyzed [22–24]. Consequently, the E\textsuperscript{rns} containing the mainly antigenic region was expressed and purified. SDS-PAGE and western blot analysis showed that the E\textsuperscript{rns} protein was efficiently glycosylated in sf21 cells. Furthermore, E\textsuperscript{rns}-specific antibody was detected in the C strain, CSFV-E\textsuperscript{rns} and CSFV-E2+E\textsuperscript{rns} groups, suggesting the obtained E\textsuperscript{rns} protein is immunogenic. The E\textsuperscript{rns} has been shown to be able to induce virus-neutralizing antibodies in the host in previous studies [10–12]. However, in a more recent work, a yeast-expressed E\textsuperscript{rns} failed to induce neutralizing antibodies in vaccinated pigs [18]. In this study, no neutralizing antibody was detected in the E\textsuperscript{rns} vaccinated rabbits either, which is consistent with the recent work. Thus, the glycosylated E\textsuperscript{rns} may not induce high neutralizing antibody titers in vaccinated groups. Since it was reported that a single dose of purified E\textsuperscript{rns} could induce protection against CSFV [7], the exact mechanism mediating the protection remains uncertain.

In this study, we analyzed the CSFV-specific T-lymphocyte proliferative response and cytokine production assay to determine if the proteins induced T-cell responses. All groups produced higher stimulation indices compared with the PBS group. IFN-\(\gamma\) (Th1-type cytokine) and IL-4 (Th2-type cytokine) were measured after stimulation to evaluate the Th1 and Th2 responses. In all the vaccine groups, stimulated T lymphocytes produced a much higher concentration of IFN-\(\gamma\) compared to IL-4. The results indicated that the CSFV-E2, CSFV-E\textsuperscript{rns}, and CSFV-\(E_2+E\textsuperscript{rns}\) groups may mainly stimulate Th1 response in rabbits.

All rabbits in the PBS group showed typical fever after CSFV challenge. The CSFV-E\textsuperscript{rns} vaccine did not produce protection, as indicated in this group by the typical fever and the presence of viral RNA in the spleen. In contrast, the rabbits of the E2 and E2+E\textsuperscript{rns} groups were completely protected from challenge infection. These results suggest that E2 protein is essential and may be sufficient for vaccine-mediated protection against CSFV.

**Conclusions**

In this study, CSFV E2 and E\textsuperscript{rns} protein were successfully generated by insect cell/baculovirus expression system and the immunogenicity of the proteins was evaluated. There was some controversy about the efficacy of the recombinant E\textsuperscript{rns} protein as subunit vaccines against CSFV. The results presented here supported the conclusion that the E\textsuperscript{rns} could not confer protection against CSFV. In contrast, the CSFV-E2+E\textsuperscript{rns} and CSFV-E2 are candidate subunit vaccines against CSFV. Thus, our study proved that the glycoprotein E2 is the most immunogenic envelope protein, and alone can protect the rabbits against CSFV in different ways.

**Abbreviations**

CSFV: Classical swine fever virus; *E. coli*: Escherichia coli; ELISA: Enzyme-linked immunosorbent assay; ANOVA: Analysis of variance; PBMCs: Peripheral blood mononuclear cells.

**Acknowledgements**

We thank Shujun Chai from Henan Academy of Agricultural Sciences for providing high-level quality of animal care.

**Authors’ contributions**

GZ, QW, YB, YS and YL designed and directed the project. QW wrote the manuscript. YB, YS, LW and YL checked and revised it. YS, WY, YS, RD, GX helped with the animal experiments and contributed to the data analysis. All authors read and approved the final manuscript.

**Funding**

This work was supported by grants from the National Key Research and Development Program of China (2016YFD0500707 and 2017YFD0501103), and the Key Scientific and Technological Research Projects of Henan Province (192102110007).

**Availability of data and materials**

All relevant information is provided in this current manuscript.

**Ethics approval and consent to participate**

Animal care and all animal experiments were approved by Animal Experiment Committee of Henan Academy of Agricultural Sciences with the approval number (SYXK 2014-0007) and were performed in compliance with all conventional animal welfare regulations and standards.
References

1. Moennig V, Floegel-Niesmann G, Greiser-Wilke I. Clinical signs and epidemiology of classical swine fever: a review of new knowledge. Vet J. 2003;165(1):11–20.
2. Meyers G, Thiel HJ, Rumenapf T. Classical swine fever virus: recovery of infectious viruses from cDNA constructs and generation of recombinant cytopathogenic defective interfering particles. J Virol. 1996;70(3):1588–95.
3. Thiel HJ, Stark R, Weiland E, et al. Hog cholera virus: molecular composition of virions from a pestivirus. J Virol. 1991;65(9):4705–12.
4. Schneider R, Unger G, Stark R, et al. Identification of a structural glycoprotein of an RNA virus as a ribonuclease. Science. 1993;261(5125):1169–71.
5. Branza-Nichita N, Lazar C, Dwek RA, et al. Role of N-glycan trimming in the folding and secretion of the pestivirus protein Erns. Biochem Biophys Res Commun. 2004;319(2):655–62.
6. Sainz IF, Holinka LG, Lu Z, et al. Removal of a N-linked glycosylation site of classical swine fever virus strain Brescia Erns glycoprotein affects virulence in swine. Virology. 2008;370(1):122–9.
7. Gavrilov BK, Rogers K, Fernandez-Sanz I, et al. Effects of glycosylation on antigenicity and immunogenicity of classical swine fever virus envelope proteins. Virology. 2011;420(1):135–45.
8. Gr R, Mv B, Gf K, et al. The E2 glycoprotein of classical swine fever virus is a virulence determinant in swine. J Virol. 2005;79(6):3787–96.
9. Hg VG, Ac V, Mm H, et al. Determinants of virulence of classical swine fever virus strain Brescia. J Virol. 2004;78(16):8812–23.
10. Weiland E, Ahl R, Stark R, et al. A second envelope glycoprotein mediates neutralization of a pestivirus, hog cholera virus. J Virol. 1992;66(6):3677–82.
11. Konig M, Lengsfeld T, Pauly T, et al. Classical swine fever virus: independent induction of protective immunity by two structural glycoproteins. J Virol. 1995;69(10):6479–86.
12. Bouma A, De Smit AJ, De Jong MC, et al. Determination of the onset of the herd-immunity induced by the E2 sub-unit vaccine against classical swine fever virus. Vaccine. 2000;18(14):1374–81.
13. Madera R, Gong W, Wang L, et al. Pigs immunized with a novel E2 subunit vaccine are protected from subgenotype heterologous classical swine fever virus challenge. BMC Vet Res. 2016;12(1):197.
14. Lin GJ, Liu TY, Tseng YY, et al. Yeast-expressed classical swine fever virus glycoprotein E2 induces a protective immune response. Vet Microbiol. 2009;139(3–4):369–74.
15. Blome S, Moss C, Reimann L, et al. Classical swine fever vaccines-state-of-the-art. Vet Microbiol. 2017;206:10–20.
16. Zang H, Li X, Peng G, et al. Glycoprotein E2 of classical swine fever virus expressed by baculovirus induces the protective immune responses in rabbits. Vaccine. 2014;32(49):6607–13.
17. Tong W, Zheng H, Li GQ, et al. Recombinant pseudorabies virus expressing E2 of classical swine fever virus (CSFV) protects against both virulent pseudorabies virus and CSFV. Antiviral Res. 2020;173:104652.
18. Lin GJ, Deng MC, Chen ZW, et al. Yeast expressed classical swine fever E2 subunit vaccine candidate provides complete protection against lethal challenge infection and prevents horizontal virus transmission. Vaccine. 2012;30(13):2336–41.
19. Blome S, Meindl-Bohmer A, Loeffen W, et al. Assessment of classical swine fever diagnostics and vaccine performance. Rev Sci Tech. 2006;25(3):1025–38.
20. Dong XN, Chen YH. Marker vaccine strategies and candidate CSFV marker vaccines. Vaccine. 2007;25(2):205–30.
21. Ganges L, Crooke HR, Bohorquez JA, et al. Classical swine fever virus: the past, present and future. Virus Res. 2020;289:198151.
22. Lin M, McRae H, Dan H, et al. High-resolution epitope mapping for monoclonal antibodies to the structural protein Erns of classical swine fever virus using peptide array and random peptide phage display approaches. J Gen Virol. 2010;91:2928–40.
23. Lin M, Trottier E, Pasick J, et al. Identification of antigenic regions of the Erns protein for pig antibodies elicited during classical swine fever virus infection. J Biochem. 2004;136(6):795–804.
24. Meyer D, Aebischer A, Muller M, et al. New insights into the antigenic structure of the glycoprotein E(0) of classical swine fever virus by epitope mapping. Virolology. 2012;433(1):45–54.
25. Fetzer C, Tews BA, Meyers G. The carboxy-terminal sequence of the pestivirus glycoprotein E(0) represents an unusual type of membrane anchor. J Virol. 2005;79(18):11901–13.
26. Tews BA, Meyers G. The pestivirus glycoprotein Erns is anchored in plane in the membrane via an amphipathic helix. J Biol Chem. 2007;282(45):32730.
27. Aberle D, Muhle-Goll C, Bück J, et al. Structure of the membrane anchor of pestivirus glycoprotein Erns: a long tilted amphipathic helix. PLoS Pathog. 2014;10(2):e1003973.
28. Wang HG, Ning YB, Ying C, et al. Development and application of a RT-nestPCR assay for differential detection of C-strain and wild-type viruses of classical swine fever virus. Sustain Agric Res. 2013;2(3):27–40.
29. Li Y, Wang J, Kanai R, et al. Crystal structure of glycoprotein E2 from pseudorabies virus and CSFV. Antiviral Res. 2020;173:104652.
30. Li X, Wang J, Kanai R, et al. Crystal structure of glycoprotein E2 from bovine viral diarrhea virus. Proc Natl Acad Sci USA. 2013;110(17):6805–10.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.